Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R31 | P59538 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | PTPN1 | P18031 | 7/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.43 |
| ▸ | PNLIP | P16233 | 2/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.41 |
| ▸ | TTL | Q8NG68 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Agathic Acid SCHEMBL21914839 | 0.88 | TAS2R31 (0.64) | TAS2R31LMNACYP3A4SMN1; SMN2PTPN1 | |
| Agathic Acid SCHEMBL30436331 | 0.88 | TAS2R31 (0.64) | TAS2R31LMNACYP3A4SMN1; SMN2PTPN1 | |
| Agathic Acid SCHEMBL29358171 | 0.88 | TAS2R31 (0.64) | TAS2R31LMNACYP3A4SMN1; SMN2PTPN1 | |
| Copalic Acid SCHEMBL25221800 | 0.88 | TAS2R31 (0.66) | TAS2R31LMNACYP3A4SMN1; SMN2PTPN1 | |
| Copalic Acid SCHEMBL29481956 | 0.88 | TAS2R31 (0.66) | TAS2R31LMNACYP3A4SMN1; SMN2PTPN1 | |
| Copalic Acid SCHEMBL34460866 | 0.88 | TAS2R31 (0.66) | TAS2R31LMNACYP3A4SMN1; SMN2PTPN1 | |
| Kayadiol SCHEMBL13039024 | 0.87 | LMNA (0.63) | TAS2R31LMNACYP3A4SMN1; SMN2PTPN1 | |
| Kayadiol SCHEMBL30320287 | 0.87 | LMNA (0.63) | TAS2R31LMNACYP3A4SMN1; SMN2PTPN1 | |
| Kayadiol SCHEMBL29357475 | 0.87 | LMNA (0.63) | TAS2R31LMNACYP3A4SMN1; SMN2PTPN1 | |
| SCHEMBL29354424 | 0.85 | TAS2R31 (0.63) | TAS2R31LMNACYP3A4SMN1; SMN2PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3600369-B1 | USE OF AN EXTRACT OF COPAIFERA AGAINST ALOPECIA | PIERRE FABRE DERMO COSMETIQUE (FR) | 2026-05-20 | — | — | EP | claimed |
| US-20260146925-A1 | SOLID PHASE EXTRACTION OF ACIDIC BIOMARKERS PRESENT IN OIL SAMPLES, SEDIMENTARY ROCK EXTRACTS, AND PLANT MATERIAL | Petróleo Brasileiro S. A. -Petrobras (BR) | 2026-05-28 | — | — | US | disclosed |
| EP-3600370-B1 | USE OF COPAIFERA OLEORESIN IN PATHOLOGIES OF THE PROSTATE | PF MEDICAMENT (FR) | 2024-04-03 | — | — | EP | disclosed |
| US-11311591-B2 | Use of copaifera oleoresin in pathologies of the prostate | PIERRE FABRE MEDICAMENT (FR) | 2022-04-26 | — | — | US | disclosed |
| US-11311591-B2 | Use of copaifera oleoresin in pathologies of the prostate | PIERRE FABRE MEDICAMENT (FR) | 2022-04-26 | — | — | US | disclosed |
| US-10925915-B2 | Use of a Copaifera extract to combat alopecia and seborrhea | PIERRE FABRE DERMO-COSMETIQUE (FR) | 2021-02-23 | — | — | US | disclosed |
| US-20200093879-A1 | USE OF COPAIFERA OLEORESIN IN PATHOLOGIES OF THE PROSTATE | PIERRE FABRE MEDICAMENT (FR) | 2020-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11311591-B2 | Use of copaifera oleoresin in pathologies of the prostate | ACP3, BPHL, CYP17A1 | TAS2R31 4363/4885LMNA 2648/4885CYP3A4 1423/4885 |
| US-10925915-B2 | Use of a Copaifera extract to combat alopecia and seborrhea | CUTA, CYP17A1, CYP51A1 | TAS2R31 2510/4885LMNA 4129/4885CYP3A4 3368/4885 |
| US-20260146925-A1 | SOLID PHASE EXTRACTION OF ACIDIC BIOMARKERS PRESENT IN OIL SAMPLES, SEDIMENTARY ROCK EXTRACTS, AND PLANT MATERIAL | SGMS2, SGMS1, CA2 | TAS2R31 1861/4885LMNA 1696/4885CYP3A4 2633/4885 |
| US-20200093879-A1 | USE OF COPAIFERA OLEORESIN IN PATHOLOGIES OF THE PROSTATE | ACP3, BPHL, CYP17A1 | TAS2R31 4363/4885LMNA 2648/4885CYP3A4 1423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.